ArticleAvicenna journal of medical biotechnology
Ethical Considerations Emerge from Artificial Intelligence (AI) in Biotechnology.
Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- [Artificial intelligence and cardiovascular biobanks: Shared technological promise and ethical responsibility].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Beyond conventional therapies: Gut microbiota modulation and macromolecular drugs in the battle against cardiometabolic diseases.Journal of pharmaceutical analysis · 2026Review
- Applications of artificial intelligence in stem cell therapy.World journal of stem cells · 2025Review
- The revolutionary impact of artificial intelligence in orthopedics: comprehensive review of current benefits and challenges.Journal of robotic surgery · 2025Review
- Machine learning and deep learning in glioblastoma: a systematic review and meta-analysis of diagnosis, prognosis, and treatment.Discover oncology · 2025Article
- Current Bioinformatics Tools in Precision Oncology.MedComm · 2025Review
- From Patterns to Pills: How Informatics Is Shaping Medicinal Chemistry.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of Artificial intelligence (AI) in biotechnology presents significant ethical challenges that must be addressed to ensure responsible innovations. Key concerns include data privacy and security, as AI systems often handle sensitive genetic and health information, necessitating robust regulations to protect individuals' rights and maintain public trust. Algorithmic bias poses another critical issue; AI can reflect existing biases in training data, leading to inequitable healthcare outcomes. Transparency in AI decision-making is essential, as "black box" models hinder trust, especially in drug discovery and genetics. Ethical implications of genetic manipulation require careful scrutiny to define the limits of human intervention. Additionally, societal impacts must be considered to ensure equitable distribution of AI benefits, preventing the exacerbation of disparities. Engaging diverse stakeholders, including ethicists and policymakers, is vital in aligning these technologies with societal values. Ultimately, prioritizing ethics will allow us to harness AI and biotechnology's potential while safeguarding human rights and promoting equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.